Summary of the Research Topic: This collection of studies explores innovative biomarkers, molecular mechanisms, and therapeutic strategies across various cancers and diseases, particularly highlighting diagnostic and treatment advances in esophageal cancer, Wilms tumor, glioblastoma, cervical cancer, basal cell carcinoma, low-grade glioma, hepatocellular carcinoma, Alzheimer's disease, Pelvic Organ Prolapse (POP), and Intervertebral Disc Degeneration (IDD). Key findings include the discovery of exosomes as diagnostic biomarkers in esophageal cancer; the potential of serum miRNAs to differentiate histopathological types of Wilms tumor; therapeutic repurposing of the M1 receptor-targeting drug Trihexyphenidyl for Glioblastoma treatment; exploration of hesperidin as a protective natural compound against IDD while mitigating cancer risks related to estrogen; identification of metabolic biomarkers through multi-omics integration linking Alzheimer's and POP; validation of lncRNAs and plasma proteins as non-invasive biomarkers for liver disease and basal cell carcinoma; elucidation of the significance of CD46 and TOP1 as prognostic and therapeutic targets in cervical cancer; and emphasizing the roles of STAT family genes in low-grade glioma progression. Collectively, these studies provide valuable insights into cancer biology, novel diagnostic tools, therapeutic targets, and the translational potential for improved patient management and outcomes.
----------------------------------------------------------------------
Research Topic Description: In the current landscape of targeted therapies, the exploration of novel targets and biomarkers holds paramount importance in advancing drug development and treatment modalities. A concerted effort is underway to comprehend the intricacies of cancer development, with the ultimate goal of expediting the discovery of groundbreaking pharmaceuticals. While some pioneering drug targets and biomarkers have already been pinpointed, the inherent heterogeneity of cancers underscores the imperative to broaden the spectrum of drugs and biomarkers. Achieving personalized treatment options hinges on this diversity. Thanks to recent strides in biological and medical technologies, there exists a newfound capability to swiftly unravel the mechanisms underpinning cancer initiation and progression, thereby unveiling novel targets. This presents a significant opportunity for the development of clinically effective anticancer drugs and biomarkers.
Beyond the identification of novel targets and biomarkers, a pivotal facet of drug development lies in comprehending how these targets interact with cancer cells, influencing their growth and survival. Such insights are instrumental in crafting drugs that can adeptly target these interactions and impede cancer progression. Furthermore, the trajectory of novel drug and biomarker development extends beyond target identification, encompassing pre-clinical and clinical trials. These trials rigorously evaluate the safety, efficacy, and pharmacokinetics of these agents, seeking to establish optimal doses, treatment schedules, and combination therapies that maximize therapeutic benefits while mitigating side effects.
The Research Topic issue on " Novel biomarkers in solid tumors and related medicine therapy" serves as a forum for disseminating the latest research findings, deliberating challenges, and charting future research directions in this domain. Submissions spanning various disciplines are encouraged, including basic and translational research, clinical trials, bioinformatics research, machine learning, meta-analysis, and drug development. By fostering a collaborative community of researchers and clinicians, our aim is to expedite the development of innovative drugs and biomarkers for the treatment of solid tumors.
• A pivotal facet of drug development lies in comprehending how these targets interact with cancer cells, influencing their growth and survival
• The trajectory of novel drug and biomarker development extends beyond target identification, encompassing pre-clinical and clinical trials
• Trials rigorously evaluate the safety, efficacy, and pharmacokinetics of these agents, seeking to establish optimal doses, treatment schedules, and combination therapies that maximize therapeutic benefits while mitigating side effects
• Basic and translational research, clinical trials, bioinformatics research, machine learning, meta-analysis, and drug development based on biomarkers of solid tumors
Summary of the Research Topic: This collection of studies explores innovative biomarkers, molecular mechanisms, and therapeutic strategies across various cancers and diseases, particularly highlighting diagnostic and treatment advances in esophageal cancer, Wilms tumor, glioblastoma, cervical cancer, basal cell carcinoma, low-grade glioma, hepatocellular carcinoma, Alzheimer's disease, Pelvic Organ Prolapse (POP), and Intervertebral Disc Degeneration (IDD). Key findings include the discovery of exosomes as diagnostic biomarkers in esophageal cancer; the potential of serum miRNAs to differentiate histopathological types of Wilms tumor; therapeutic repurposing of the M1 receptor-targeting drug Trihexyphenidyl for Glioblastoma treatment; exploration of hesperidin as a protective natural compound against IDD while mitigating cancer risks related to estrogen; identification of metabolic biomarkers through multi-omics integration linking Alzheimer's and POP; validation of lncRNAs and plasma proteins as non-invasive biomarkers for liver disease and basal cell carcinoma; elucidation of the significance of CD46 and TOP1 as prognostic and therapeutic targets in cervical cancer; and emphasizing the roles of STAT family genes in low-grade glioma progression. Collectively, these studies provide valuable insights into cancer biology, novel diagnostic tools, therapeutic targets, and the translational potential for improved patient management and outcomes.
----------------------------------------------------------------------
Research Topic Description: In the current landscape of targeted therapies, the exploration of novel targets and biomarkers holds paramount importance in advancing drug development and treatment modalities. A concerted effort is underway to comprehend the intricacies of cancer development, with the ultimate goal of expediting the discovery of groundbreaking pharmaceuticals. While some pioneering drug targets and biomarkers have already been pinpointed, the inherent heterogeneity of cancers underscores the imperative to broaden the spectrum of drugs and biomarkers. Achieving personalized treatment options hinges on this diversity. Thanks to recent strides in biological and medical technologies, there exists a newfound capability to swiftly unravel the mechanisms underpinning cancer initiation and progression, thereby unveiling novel targets. This presents a significant opportunity for the development of clinically effective anticancer drugs and biomarkers.
Beyond the identification of novel targets and biomarkers, a pivotal facet of drug development lies in comprehending how these targets interact with cancer cells, influencing their growth and survival. Such insights are instrumental in crafting drugs that can adeptly target these interactions and impede cancer progression. Furthermore, the trajectory of novel drug and biomarker development extends beyond target identification, encompassing pre-clinical and clinical trials. These trials rigorously evaluate the safety, efficacy, and pharmacokinetics of these agents, seeking to establish optimal doses, treatment schedules, and combination therapies that maximize therapeutic benefits while mitigating side effects.
The Research Topic issue on " Novel biomarkers in solid tumors and related medicine therapy" serves as a forum for disseminating the latest research findings, deliberating challenges, and charting future research directions in this domain. Submissions spanning various disciplines are encouraged, including basic and translational research, clinical trials, bioinformatics research, machine learning, meta-analysis, and drug development. By fostering a collaborative community of researchers and clinicians, our aim is to expedite the development of innovative drugs and biomarkers for the treatment of solid tumors.
• A pivotal facet of drug development lies in comprehending how these targets interact with cancer cells, influencing their growth and survival
• The trajectory of novel drug and biomarker development extends beyond target identification, encompassing pre-clinical and clinical trials
• Trials rigorously evaluate the safety, efficacy, and pharmacokinetics of these agents, seeking to establish optimal doses, treatment schedules, and combination therapies that maximize therapeutic benefits while mitigating side effects
• Basic and translational research, clinical trials, bioinformatics research, machine learning, meta-analysis, and drug development based on biomarkers of solid tumors